MHI
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research
The companies are working together on cellular medicines to boost, replace or repair biological functions
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients
Approximately 38.4 million people in the US are affected by diabetes
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
The companies will aim to discover and develop new therapeutics for the group of disorders
Eli Lilly shares promising phase 3 results for once-weekly insulin candidate efsitora alfa
The company is planning to submit regulatory applications for the candidate by the end of the year
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition
The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD
NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study
The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate
Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn
The candidate is being evaluated in a phase 3 obesity trial and phase 2b diabetes study
Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease
Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Cardiovascular diseases result in an estimated 17.9 million global deaths each year
AstraZeneca announces $2.5bn investment in China to boost R&D capabilities
The funds will go towards a new global research and development centre in Beijing’s BioPark